BLU — BELLUS Health Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMid Cap
- $1.87bn
- $1.56bn
- $0.02m
Brief: Bellus Health Reports Qtrly Loss Per Share Of $0.03
Brief: Bellus Health Qtrly Loss Per Share $0.01
Brief: Bellus Health Initiates Phase 1 Clinical Study For Its Chronic Cough Drug Candidate, BLU-5937
Brief: Bellus Health Inc Reports Qtrly Loss Per Share $0.02
Brief: Bellus Health Receives Milestone Payment From Taro Pharmaceuticals
Brief: Bellus Health Prices $20 Mln Equity Offering At $0.38/Shr
Brief: Bellus health reports qtrly share of $0.03
Brief: Bellus Health appoints Dr Clarissa Desjardins to its board of directors
Brief: Bellus Health's BLU-5937 reduces cough without taste disturbance in two preclinical models
Brief: Bellus Health Q2 revenue $41,000
Brief: Bellus Health to sell subsidiary Thallion Pharmaceuticals to Taro Pharmaceuticals
Brief: Bellus Health reports results for the year ended December 31, 2016
Brief: Bellus Health and the NEOMED Institute announce agreement for development of treatment for chronic cough
Brief: Bellus Health provides update on pipeline
Brief: BELLUS Health qtrly loss per share $0.01
Brief: Bellus Health reports Q2 basic and diluted loss per share $0.01
Brief: Bellus Health says Kiacta did not meet primary efficacy endpoint in phase 3 study
Brief: Bellus Health says Pharmascience to convert 10.4 pct interest in BHI Limited Partnership
Brief: Bellus Health reports Q1 loss per share C$0.01